一二三四在线视频社区8,一二三四在线播放免费观看高清电影,国产精品日韩在线观看,桃花视频

<big id="ia5w5"><em id="ia5w5"></em></big>

  • <pre id="ia5w5"></pre>
    <pre id="ia5w5"></pre>
    1. <center id="ia5w5"><em id="ia5w5"><track id="ia5w5"></track></em></center>

        <object id="ia5w5"><sup id="ia5w5"><sub id="ia5w5"></sub></sup></object><big id="ia5w5"><nobr id="ia5w5"></nobr></big>
        <big id="ia5w5"></big>
        • Technology platforms
          Synthetic vaccine technology
          Our Synthetic vaccine technology and process know-how enable us to manufacture a wide range of conjugate vaccines. In addition to commonly used DT and TT carrier proteins, we have a number of carrier proteins including CRM197, which is produced by our proprietary high-yield bacterial strain and used in our MCV candidates. Our wide range of carrier proteins allows us to develop better multi-v
          Viral vector-based technology
          This technology enabled us to translate our globally innovative Ebola virus vaccine from a concept to an approved product in only three years. Our adenovirus-based vector technology is also applied to our TB Booster and other vaccine candidates.
        • Technology platforms
          mRNA vaccine technology
          The mRNA technology has significant advantages in the R&D process and production cycles, including fast, scalable and uniform production. mRNA vaccines use antigen-encoding messenger RNA to induce humoral and cellular immunity through specific delivery systems that enable cells to take up and express the encoded antigen.It can act on intracellular and extracellular targets and express a variety of proteins without entering the nucleus and not requiring in vitro expression and purification. The development of mRNA vaccines only requires the replacement of the antigen sequence on a mature technology platform, which shows great advantages in dealing with public health emergency. CanSinoBIO’s COVID-19 mRNA vaccine and other prophylactic virus vaccine candidates are developed upon this platform.
          Protein structure design and recombinant VLP technology
          We have used protein structure design technology to design pneumococcal protein antigens. In addition, we have developed novel recombinant strains to produce a new generation pertussis vaccine. We also developed a proprietary cell line to be used for viral vector production.
        • Technology platforms
          Formulation and delivery technology
          Our culture media formulations are free from animal components, and our final product formulations are free from undesired phenol and preservatives. Such characteristics ensure consistent product quality and reduce potential risks of side effects.
        <big id="ia5w5"><em id="ia5w5"></em></big>

      1. <pre id="ia5w5"></pre>
        <pre id="ia5w5"></pre>
        1. <center id="ia5w5"><em id="ia5w5"><track id="ia5w5"></track></em></center>

            <object id="ia5w5"><sup id="ia5w5"><sub id="ia5w5"></sub></sup></object><big id="ia5w5"><nobr id="ia5w5"></nobr></big>
            <big id="ia5w5"></big>
          1. 一二三四在线视频社区8,一二三四在线播放免费观看高清电影,国产精品日韩在线观看,桃花视频

            品牌简介

            {转码主词}